keyword
https://read.qxmd.com/read/38570342/neoadjuvant-in-situ-and-systemic-immunotherapy-with-lymph-node-cryoablation-in-resectable-stage-iii-melanoma-metastasis-a-proof-of-concept-study
#1
JOURNAL ARTICLE
Antoine Braud, Pierre Auloge, Nicolas Meyer, Caroline Bouvrais, Mousselim Gharbi, Hervé Lang, Afshin Gangi, Dan Lipsker
PURPOSE: Complete lymph node dissection is the recommended treatment for clinically detectable lymph nodes in stage III melanoma. This surgery is associated with substantial morbidity. We hypothesize that combining percutaneous imaging-guided cryoablation of locoregional lymph nodes metastases with neoadjuvant in situ and systemic immunotherapy could allow disease control and evaluate the feasibility of this combination in this proof-of-concept study. METHODS: We enrolled 15 patients with stage IIIB/IIIC melanoma...
April 3, 2024: Cardiovascular and Interventional Radiology
https://read.qxmd.com/read/38185710/economic-evaluation-of-percutaneous-cryoablation-vs-conventional-surgery-in-extra-abdominal-desmoid-tumours-in-the-spanish-healthcare-system
#2
JOURNAL ARTICLE
José Antonio Narvaez, Daniel Bernabeu, Lorenzo Muntaner, Fernando Gomez, José Martel, María Del Mar Castellano, Raúl García-Marcos, Reda Britel, Itziar Oyagüez, Nerea Tejado, Eduardo Ortiz-Cruz
BACKGROUND: Desmoid tumours (DTs) or deep fibromatosis are benign soft-tissue tumours, sometimes locally aggressive, requiring intervention on some cases. Surgery has been the gold standard, but new less invasive techniques such as percutaneous cryoablation have proved their effectiveness, reducing health resources and complications. The study aimed to compare the total cost of percutaneous cryoablation and conventional surgery for patients with extra-abdominal and/or abdominal wall DTs, candidates for local ablative treatment in Spain...
January 7, 2024: Insights Into Imaging
https://read.qxmd.com/read/37684178/nephron-sparing-treatment-nest-for-small-renal-masses-a-feasibility-cohort-embedded-randomised-controlled-trial-comparing-percutaneous-cryoablation-and-robot-assisted-partial-nephrectomy
#3
JOURNAL ARTICLE
Joana B Neves, Hannah Warren, Joseph Santiapillai, Nicola Rode, David Cullen, Menelaos Pavlou, Miles Walkden, Prasad Patki, Ravi Barod, Faiz Mumtaz, Michael Aitchison, Steven Bandula, Elena Pizzo, Veronica Ranieri, Norman Williams, William Wildgoose, Kurinchi Gurusamy, Mark Emberton, Axel Bex, Maxine G B Tran
There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled in the RCT. In the RCA intervention arm, 84% consented (95% confidence interval [CI] 64-95%) and 76% (95% CI 55-91%) received CRA; 100% (95% CI 86-100%) of the control arm underwent RPN...
September 6, 2023: European Urology
https://read.qxmd.com/read/37671163/cryoablation-and-immunity-in-non-small-cell-lung-cancer-a-new-era-of-cryo-immunotherapy
#4
REVIEW
Antonio Velez, Andrew DeMaio, Daniel Sterman
Despite remarkable advances in tumor response and patient survival in the past decade, systemic immunotherapies for lung cancer result in an objective response in only around half of patients treated. On the basis of this limitation, combination strategies are being investigated to improve response rates. Cryoablation has been proposed as one such technique to induce immunogenic cell death and synergize with systemic immunotherapies, including immune checkpoint inhibitors. Cryoablation has been traditionally delivered percutaneously with imaging guidance although recent technological advances allow for bronchoscopic delivery...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37370049/endophytic-upper-tract-urothelial-carcinoma-in-a-solitary-kidney-treated-by-cryotherapy-an-unorthodox-case-for-successful-management
#5
JOURNAL ARTICLE
Ahmad Abdelaziz, Mark Sultan, Muhammed A Hammad, Juan Ramon Martinez, Maria Yacoub, Ramy F Youssef
BACKGROUND: Nephroureterectomy remains the gold standard treatment for upper tract urothelial carcinoma (UTUC). Considering the high risk of developing renal function impairment after surgery, the rationale for nephron sparing approaches in treatment of UTUC has been raised. In this case, renal cryoablation was able to achieve successful oncologic control while preserving renal function during 5 years of follow up without intraoperative or post operative complications. CASE PRESENTATION: A 79 year old male presents after three months of macroscopic hematuria...
June 27, 2023: BMC Urology
https://read.qxmd.com/read/37189680/the-role-of-ablative-techniques-in-the-management-of-hepatocellular-carcinoma-indications-and-outcomes
#6
REVIEW
Asanda Koza, Ricky H Bhogal, Nicos Fotiadis, Vasileios K Mavroeidis
The management of hepatocellular carcinoma (HCC) remains complex and will continue to rely on the multidisciplinary input of hepatologists, surgeons, radiologists, oncologists and radiotherapists. With the appropriate staging of patients and selection of suitable treatments, the outcomes for HCC are improving. Surgical treatments encompassing both liver resection and orthotopic liver transplantation (OLT) are the definitive curative-intent options. However, patient suitability, as well as organ availability, pose essential limitations...
March 31, 2023: Biomedicines
https://read.qxmd.com/read/37169604/-nephron-sparing-in-the-management-of-localized-solid-renal-mass
#7
REVIEW
Sylvain Bodard, Charles Dariane, Jean-Emmanuel Bibault, Idris Boudhabhay, Christophe Delavaud, Marc-Olivier Timsit, Virginie Verkarre, Arnaud Méjean, Olivier Hélénon, Sylvain Guinebert, Jean-Michel Correas
Managing a malignant renal tumor requires, first of all, a reflection on the necessity of its treatment. It must consider the renal function, altered at the time of diagnosis in 50% of cases. The treatment method chosen depends on many factors, in particular, the predicted residual renal function, the risk of chronic kidney disease, the need for temporary or long-term dialysis, and overall long-term survival. Other factors include the size, position, and number of tumors and a hereditary tumor background. When a renal-sparing management alternative is available, total nephrectomy should no longer be performed in patients with small malignant renal masses (cT1a)...
May 9, 2023: Bulletin du Cancer
https://read.qxmd.com/read/36994482/diagnostic-accuracy-of-percutaneous-core-biopsy-before-cryoablation-for-small-sized-renal-cell-carcinoma
#8
JOURNAL ARTICLE
Yasuhiro Ushijima, Akihiro Nishie, Nobuhiro Fujita, Yuichiro Kubo, Keisuke Ishimatsu, Kousei Ishigami
PURPOSE: To retrospectively determine the diagnostic accuracy of a percutaneous core biopsy performed before cryoablation for small-sized renal cell carcinoma. METHODS: In this study, 216 patients underwent a percutaneous core biopsy for 242 renal lesions suspected to be renal cell carcinoma on image findings before cryoablation at Kyushu University Hospital. We calculated the success rate of the histological diagnosis and investigated factors that may have contributed to the diagnostic success...
December 12, 2022: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://read.qxmd.com/read/36831543/ablative-therapy-in-non-hcc-liver-malignancy
#9
REVIEW
Tyler P Robinson, Travis Pebror, Matthew E Krosin, Leonidas G Koniaris
Surgical extirpation of liver tumors remains a proven approach in the management of metastatic tumors to the liver, particularly those of colorectal origin. Ablative, non-resective therapies are an increasingly attractive primary therapy for liver tumors as they are generally better tolerated and result in far less morbidity and mortality. Ablative therapies preserve greater normal liver parenchyma allowing better post-treatment liver function and are particularly appropriate for treating subsequent liver-specific tumor recurrence...
February 14, 2023: Cancers
https://read.qxmd.com/read/36709639/systemic-treatment-with-or-without-ablative-therapies-in-oligometastatic-breast-cancer-a-single-institution-analysis-of-patient-outcomes
#10
JOURNAL ARTICLE
Gauthier Glemarec, Jean-Louis Lacaze, Bastien Cabarrou, Richard Aziza, Eva Jouve, Slimane Zerdoud, Eleonora De Maio, Carole Massabeau, Maxime Loo, Vincent Esteyrie, Mony Ung, Florence Dalenc, Francoise Izar, Ciprian Chira
PURPOSE: Local ablative treatment (LAT) is increasingly combined with systemic therapy in oligometastatic breast cancer (OMBC), without a high-level evidence to support this strategy. We evaluated the addition of LAT to systemic treatment in terms of progression-free survival (PFS) and overall survival (OS). Secondary endpoints were local control (LC) and toxicity. We sought to identify prognostic factors associated with longer OS and PFS. METHODS AND MATERIALS: We identified consecutive patients treated between 2014 and 2018 for synchronous or metachronous OMBC (defined as ≤ 5 metastases)...
February 2023: Breast: Official Journal of the European Society of Mastology
https://read.qxmd.com/read/36699749/ultrasound-guided-percutaneous-cryoneurolysis-for-post-thoracotomy-pain-syndrome-a-case-report
#11
Joshua Perese, Jessica Oswald, Rodney A Gabriel
Post-thoracotomy pain syndrome (PTPS) is a post-operative thoracotomy complication that is difficult to treat. We describe the first-time use of ultrasound-guided percutaneous cryoneurolysis of the intercostal nerves to successfully treat PTPS refractory to conventional medications and interventions. We report a case of a 40-year-old male with two years of severe PTPS sustained after undergoing a thoracotomy. Treatment with intercostal cryoneurolysis resulted in an immediate 75% improvement in pain for six weeks followed by sustained 50% pain relief for eight weeks...
December 2022: Curēus
https://read.qxmd.com/read/36477612/endoscopic-balloon-cryoablation-plus-transurethral-resection-for-bladder-cancer-a-phase-2-multicenter-randomized-controlled-trial
#12
JOURNAL ARTICLE
Chenyang Xu, Shuai Jiang, Lujia Zou, Lu Sheng, Guowei Shi, Bin Xu, Zhong Wang, Danfeng Xu, Xin Xie, Jianfeng Luo, Jianming Guo, Haowen Jiang
BACKGROUND: Cryotherapy is a prevalent percutaneous ablative therapy for solid tumors. Here, we report a novel device using liquid nitrogen for endoscopic cryotherapy of bladder cancer. METHODS: In this multicenter, randomized, parallel controlled, Phase 2 trial, we compared endoscopic balloon cryoablation (EBCA) with a single instillation (SI) of pirarubicin after transurethral resection (TUR). Eligible participants were randomly assigned (1:1) to the TUR-EBCA or TUR-SI group...
December 7, 2022: Cancer
https://read.qxmd.com/read/36381158/prospective-long-term-experience-in-the-treatment-of-renal-tumors-with-cryotherapy-follow-up-with-computed-tomography-scan-and-contrast-enhanced-ultrasound
#13
JOURNAL ARTICLE
Inés Laso-García, Fernando Arias-Fúnez, Marta Santiago-González, Enrique Sanz-Mayayo, Gema Duque-Ruiz, Manuel Hevia-Palacios, Victoria Gómez-Dos-Santos, Andreina Olavarria-Delgado, Ana Palomera-Rico, Francisco Javier Burgos-Revilla
Introduction: The aim of this article was to evaluate the oncological results and safety of cryotherapy for the treatment of renal tumors. Material and methods: This study was a prospective review and follow-up of patients who underwent cryotherapy from January 2008 to May 2021. Cryotherapy was offered to patients with bilateral tumors, tumors in solitary kidneys, or comorbid patients. Follow-up consisted of a computed tomography (CT) scan and contrast-enhanced ultrasound (CEUS), with analysis of concordance (kappa index)...
2022: Central European Journal of Urology
https://read.qxmd.com/read/36035784/management-of-juxta-articular-chondroblastoma-letter-to-editor
#14
JOURNAL ARTICLE
Karthikeyan P Iyengar, R Botchu
No abstract text is available yet for this article.
September 2022: Journal of Clinical Orthopaedics and Trauma
https://read.qxmd.com/read/35899088/-cryptococcus-granuloma-mimicking-local-progressed-tumor-after-cryoablation-of-renal-cell-carcinoma-a-case-report
#15
Hikari Fukui, Masashi Fujimori, Takashi Yamanaka, Naritaka Matsushita, Seiya Kishi, Chisami Nagata, Yuki Omori, Kouhei Nishikawa, Hiroto Yuasa, Hajime Sakuma
Infectious granulomas arising in the kidney are rare. However, there are few reports regarding renal granulomas, such as xanthogranulomatous pyelonephritis, sarcoidosis, malakoplakia, and tuberculosis. Here, we report a case of cryptococcal granuloma resembling a locally progressed tumor after percutaneous cryotherapy for renal cell carcinoma. A male patient in his 80s with rheumatoid arthritis underwent computed tomography (CT)-guided cryoablation for biopsy-proven papillary renal cell carcinoma. Follow-up contrast-enhanced CT imaging obtained 4 months after ablation confirmed an enhanced mass on the edge of the ablation zone...
September 2022: Radiology Case Reports
https://read.qxmd.com/read/35686812/a-comparison-of-percutaneous-ablation-therapy-to-partial-nephrectomy-for-ct1a-renal-cancers-results-from-the-canadian-kidney-cancer-information-system
#16
JOURNAL ARTICLE
Braden Millan, Rodney H Breau, Bimal Bhindi, Ranjeeta Mallick, Simon Tanguay, Antonio Finelli, Luke T Lavallée, Frédéric Pouliot, Ricardo Rendon, Alan I So, Lucas Dean, Jean-Baptiste Lattouf, Naveen S Basappa, Anil Kapoor
PURPOSE: Percutaneous ablation therapy (AT) and partial nephrectomy (PN) are successful management strategies for T1a renal cancer. Our objective was to compare AT to PN with respect to recurrence-free survival (RFS) and overall survival (OS). MATERIALS AND METHODS: Patients post-PN or -AT for cT1aN0M0 renal cancer from 2011 to 2021 were identified from the national Canadian Kidney Cancer information system. Inverse probability of treatment weighting (IPTW) using propensity score (PS) was used...
October 2022: Journal of Urology
https://read.qxmd.com/read/35545102/update-on-percutaneous-local-ablative-procedures-for-the-treatment-of-hepatocellular-carcinoma
#17
JOURNAL ARTICLE
Lukas Luerken, Michael Haimerl, Michael Doppler, Wibke Uller, Lukas Philipp Beyer, Christian Stroszczynski, Ingo Einspieler
BACKGROUND:  Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Because many hepatocellular carcinomas are already unresectable at the time of initial diagnosis, percutaneous tumor ablation has become established in recent decades as a curative therapeutic approach for very early (BCLC 0) and early (BCLC A) HCC. The aim of this paper is to provide a concise overview of the percutaneous local ablative procedures currently in use, based on their technical characteristics as well as clinical relevance, taking into account the current body of studies...
May 11, 2022: RöFo: Fortschritte Auf Dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
https://read.qxmd.com/read/34908770/intralesional-agents-in-dermatology-pros-and-cons
#18
REVIEW
Jagdish Sakhiya, Dhruv Sakhiya, Jitesh Kaklotar, Bansi Hirapara, Madhav Purohit, Krishna Bhalala, Feral Daruwala, Nimish Dudhatra
Since introduced in 1961, intralesional (IL) agent has become an essential part of the dermatological practice. The term IL referred to the direct delivery of agent percutaneously into skin lesions. This therapeutic approach is relatively safe, easy to perform and applicable for a broad range of dermatological conditions. On the other hand, immediate side effects, including pain during administration, bleeding, high risk of infection and allergic reaction, and subsequent side effects involving skin changes such as atrophy, telangiectasia, pigmentary changes, and striae are usually associated with this modality...
2021: Journal of Cutaneous and Aesthetic Surgery
https://read.qxmd.com/read/34854067/microneedling-and-its-use-in-hair-loss-disorders-a-systematic-review
#19
REVIEW
Robert S English, Sophia Ruiz, Pedro DoAmaral
INTRODUCTION: Microneedling (MN) is a minimally invasive procedure involving the induction of percutaneous wounds with medical-grade needles. In this literature review, we investigate clinical data on MN for the treatment of hair loss disorders. METHODS: A literature search was conducted through PubMed up to November 2021 to identify original articles evaluating the use of MN on hair loss disorders. The database was searched using the following keywords: "microneedling," "micro needling," "micro needle," "microneedle," "needle," "dermaroller" and "alopecia," "hair loss," "alopecia," "areata," "cicatricial," or "effluvium," RESULTS: A total of 22 clinical studies featuring 1127 subjects met our criteria for inclusion...
January 2022: Dermatology and Therapy
https://read.qxmd.com/read/34590940/intraoperative-cryotherapy-in-the-treatment-of-metastatic-renal-cell-carcinoma-of-the-bone
#20
JOURNAL ARTICLE
Alec Sundet, Jodi McConnell, Kyle Walker, Bennie Lindeque
Osseous metastases in renal cell carcinoma (RCC) are a heterogeneous mix of cells with hypervascular and rapidly destructive properties that frequently exhibit resistance to both radiation and chemotherapy. Despite this, some patients with isolated and oligometastatic disease have the potential to be cured. Regardless, aggressive metastatic control is critical to minimizing morbidity and mortality for all patients with metastatic RCC. Percutaneous cryoprobes were developed as a minimally invasive technique for both pain relief and tumor control...
2021: Orthopedics
keyword
keyword
14486
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.